UK's Crackdown On Anti-Competitive Deals Continues; Actavis In Firing Line Again

 
• By Lucie Ellis-Taitt

The UK's competition authority is keen to expose supposed pay-for-delay deals made by pharmaceutical firms, and is warning drug suppliers to think twice before attempting agreements that slow the entry of generic products onto the UK market.

Wooden tower
UK competition authority continues to dismantal 'pay-for-delay' cases • Source: Shutterstock

More from Drug Pricing

More from Scrip